Zhang H, Rizk DV, Perkovic V, Maes B, et al. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 2023 Oct 30:S0085-2538(23)00754-8. doi: 10.1016/j.kint.2023.
PMID: 37914086